UCBJY - UCB SA

Other OTC - Other OTC Delayed Price. Currency in USD
38.04
0.00 (0.00%)
At close: 11:46AM EDT
Stock chart is not supported by your current browser
Previous Close38.04
Open37.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range38.04 - 38.04
52 Week Range37.60 - 46.69
Volume24
Avg. Volume618
Market Cap14.14B
Beta (3Y Monthly)0.68
PE Ratio (TTM)14.09
EPS (TTM)2.70
Earnings DateN/A
Forward Dividend & Yield0.68 (1.78%)
Ex-Dividend Date2019-04-26
1y Target EstN/A
Trade prices are not sourced from all markets
  • Bloomberg

    How an Obscure Rubber Company Became a Linchpin of Tech Industry

    (Bloomberg) -- Terms of Trade is a daily newsletter that untangles a world embroiled in trade wars. Sign up here. When Japan decided to step up its fight with South Korea last month, it dug deep into the supply chain to impose sanctions on three obscure materials made by a handful of Japanese companies few have ever heard of.The most powerful weapon in Tokyo’s campaign against its neighbor turned out to be a half-dozen or so niche firms with names like JSR Corp., Shin-Etsu Chemical Co. and Tokyo Ohka Kogyo Co. They make fluorinated polyimide, hydrogen fluoride and photo-resist: essential ingredients for the manufacture of the displays and semiconductors that go into every piece of modern consumer electronics, from Apple Inc. iPhones and Dell Technologies Inc. laptops to the full range of Samsung Electronics Co. devices. Japan prohibited the export of those materials, allowing an exception only if suppliers secure a license and renew that license regularly.How did they become so indispensable? And how did they manage to stay on top even after their Japanese clients ceded the chip and display markets to Taiwanese and South Korean rivals? The answer lies in a series of well-timed investments decades ago, combined with a willingness to explore foreign markets and an unceasing refinement of manufacturing standards too exacting for anyone else to try and match.“JSR is an interesting case in that they became big in photo-resists because they succeeded overseas first,” said Damian Thong, an analyst at Macquarie Group Ltd. “And much of this success was because of the strategy of one man — Mitsunobu Koshiba.”The JSR chairman’s story shows just how hard it would be for a newcomer to fill the shoes of one of these suppliers. Koshiba spearheaded the company’s pivot into photo-resists, a light-sensitive liquid used to imprint circuits as narrow as a few strands of DNA onto silicon wafers in a process called lithography. Gadgets keep getting slimmer, more powerful and cheaper because chip companies are able to etch ever smaller circuit patterns onto silicon. When it comes to the most advanced chip processes, JSR is one of the few that can deliver the goods.When 25-year-old Koshiba joined JSR in 1981, the company’s biggest business was still tire rubber. (The name is an abbreviation of Japan Synthetic Rubber.) As luck would have it, photo-resist at that time used resins that JSR had access to for its existing business, and the company saw an opportunity to break into a new growth industry. Japanese semiconductor makers were just beginning their rise to global dominance, and suppliers were positioning themselves to go along for the ride.The problem for JSR was it didn’t belong to any of the local keiretsu, a grouping of suppliers that receives preferential access to contracts. And the company was also up against Tokyo Ohka or TOK, the first in Japan to manufacture photo-resist. By the mid-1980s, TOK controlled as much as 90% of the domestic market.“As a neutral company without keiretsu affiliations, we had to look outside Japan,” Koshiba said in an interview, outlining JSR’s decades-long rise but declining to talk in detail about sensitive trade negotiations now underway between Tokyo and Seoul.JSR’s decision to get into that market was bold but Koshiba seemed like the right person for the job. He’d spent two years studying materials science at the University of Wisconsin-Madison on a Rotary Club scholarship, was one of the few English speakers at the company and was eager to work abroad. In 1990, JSR sent him to Belgium to set up a photo-resist joint venture with the country’s biopharmaceutical giant UCB SA. The goal was to target the American market.As timing would have it, JSR was going overseas just as Japan was approaching the peak of its semiconductor prowess. That same year, NEC Corp., Toshiba Corp. and Hitachi Ltd. were the world’s biggest chipmakers, pushing aside Intel Corp. and Texas Instruments Inc. Japanese firms occupied six spots in the industry’s top 10 ranking by revenue, a level of concentration that hasn’t been matched by any country since, according to IC Insights.Japan’s seemingly unshakable control of the computer memory market gave the country renewed national confidence. The mood was reflected in the book “The Japan That Can Say No,” in which right-wing politician Shintaro Ishihara and Sony Corp. co-founder Akio Morita argued for a more muscular foreign policy. In an eerie echo of recent events, the authors contended that the Japanese government had the power to determine the outcome of the Cold War just by directing its national companies to sell the chips used in intercontinental ballistic missiles (ICBMs) to the Soviets instead of the U.S.But the Cold War ended before that theory could be tested. Over the following decade, personal computers overtook ICBMs as the primary destination for chips and demand shifted to prioritize low unit costs over military-spec quality. By 2006, Samsung had risen to No. 2 on the list of the world’s biggest chipmakers, with Korean compatriot SK Hynix Inc. ranking seventh and only three Japanese names remaining among the top 10.For JSR, the turning point came in 2000. Koshiba, who was based in California at that time, recalls being dragged into an emergency meeting on a Sunday wearing a T-shirt and shorts. Word was a rival company was about to clinch an agreement with IBM for joint research on a next-generation photo-resist material. “Get it back,” he was told. Koshiba leaned on the network of American industry contacts he had spent a decade building, people who had known him through the worst of U.S.-Japanese trade tensions. Within a month, IBM signed with JSR.“Without that deal, we wouldn’t have gotten to No. 1,” Koshiba said.In lithography, the formula for shrinking transistors has only two levers: increase the light power or use a lens that lets more light through. Every time the chip process shifts to a higher-energy band of light, resist makers have to go back to the drawing board, opening up new opportunity. The research partnership with IBM ushered in the fourth such shift since integrated circuits replaced vacuum tubes in the 1970s, and JSR rode it all the way to the top.The company now commands about 40% of the market for the latest generation of resist used in mass production. It also supplies more than 30% of the photo-resist for 3D NAND, the most advanced flash memory chips, which are among the few product lines where Japan still competes with Korean rivals. In 2019, JSR is expected to generate about three times the revenue and five times the profit it did in the early ‘90s.What makes this business inaccessible to newcomers is the extreme degree of purity and quality demanded by customers. TOK says a single drop of coffee in two Olympic-sized swimming pools would be considered an unacceptable defect. JSR’s analogy is to a handful of tainted golf balls being enough to spoil a batch the size of the entire Japanese archipelago.In addition to being technically challenging, the markets these companies operate in are small and don’t promise fantastic growth. According to research firm Fuji Keizai Group, the industry’s sales rose just shy of 8% last year to $1.3 billion. Koshiba jokes that even the market for ramen noodles is bigger than that.“To recreate JSR, you basically need to spend as much as they did in the past 20 years on R&D and relationships, and also rebuild their reputation,” Macquarie’s Thong said. “These materials are used in such moderate quantities that to rebuild the whole infrastructure is probably not worth the investment.”And that’s the irony of the current situation. By stoking trade tensions, Japan may encourage its neighbor to subsidize competition to JSR and TOK that wouldn’t make sense under normal market conditions. It’s a matter of survival: Korean corporations now depend on Japan for over 90% of all the fluorinated polyimide and resists they need, and 44% of hydrogen fluoride requirements, Societe Generale estimates.Read more: Japan Grants South Korea Export License, Lessening Trade FearsFor the time being, JSR and TOK retain dominance over one prized material that keeps the consumer electronics industry ticking. According to South Korean Prime Minister Lee Nak-yon, Japan has approved exports of photo-resist for the next-generation of lithography currently under development by Samsung and Taiwan Semiconductor Manufacturing Co. But one of Japan’s last strongholds of tech industry domination may be under threat.“They have the engineers, and once national pride is involved they can possibly make it even if it loses money,” Koshiba said. “We don’t have an impregnable wall.”\--With assistance from Jason Clenfield.To contact the reporters on this story: Pavel Alpeyev in Tokyo at palpeyev@bloomberg.net;Yuki Furukawa in Tokyo at yfurukawa13@bloomberg.netTo contact the editors responsible for this story: Peter Elstrom at pelstrom@bloomberg.net, Vlad Savov, Edwin ChanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • The UCB (EBR:UCB) Share Price Is Down 11% So Some Shareholders Are Getting Worried
    Simply Wall St.

    The UCB (EBR:UCB) Share Price Is Down 11% So Some Shareholders Are Getting Worried

    The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

  • UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
    PR Newswire

    UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers

    BRUSSELS , July 25, 2019 /PRNewswire/ -- – Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER 1 ) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted 2  +11%, +7% CER) Underlying ...

  • What To Know Before Buying UCB SA (EBR:UCB) For Its Dividend
    Simply Wall St.

    What To Know Before Buying UCB SA (EBR:UCB) For Its Dividend

    Dividend paying stocks like UCB SA (EBR:UCB) tend to be popular with investors, and for good reason - some research...

  • Here's What UCB SA's (EBR:UCB) P/E Ratio Is Telling Us
    Simply Wall St.

    Here's What UCB SA's (EBR:UCB) P/E Ratio Is Telling Us

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...

  • PR Newswire

    Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU

    THOUSAND OAKS, Calif. and BRUSSELS, June 27, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application for EVENITYTM (romosozumab) for the treatment of severe osteoporosis. "After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year,1 and these fractures can be life-changing.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • PR Newswire

    UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

    -- New Phase 2b bimekizumab data showed the novel investigational molecule delivered improvements in disease activity and in important patient-reported outcomes, such as pain, fatigue, morning stiffness, ...

  • What Do Analysts Think About The Future Of UCB SA's (EBR:UCB)?
    Simply Wall St.

    What Do Analysts Think About The Future Of UCB SA's (EBR:UCB)?

    In December 2018, UCB SA (EBR:UCB) released its earnings update. Generally, the consensus outlook from analysts appear...

  • UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
    PR Newswire

    UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

    - NAYZILAM® (midazolam) nasal spray CIV is a nasally administered benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, ...

  • A Look At The Intrinsic Value Of UCB SA (EBR:UCB)
    Simply Wall St.

    A Look At The Intrinsic Value Of UCB SA (EBR:UCB)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • UCB SA (EBR:UCB): Ex-Dividend Is In 3 Days
    Simply Wall St.

    UCB SA (EBR:UCB): Ex-Dividend Is In 3 Days

    If you are interested in cashing in on UCB SA's (EBR:UCB) upcoming dividend of €0.85 per share, you only have 3 days left to buy the shares before its ex-dividend date, 26 April 2019, in time for dividends payable on the 30 April 2019...

  • PR Newswire

    FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

    THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.

  • A Note On UCB SA's (EBR:UCB) ROE and Debt To Equity
    Simply Wall St.

    A Note On UCB SA's (EBR:UCB) ROE and Debt To Equity

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for th...

  • PR Newswire

    CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

    FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with CIMZIA compared to placebo. BRUSSELS, March 28, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA® (certolizumab pegol) to include a new indication for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The approval makes CIMZIA the first and only FDA-approved  treatment for nr-axSpA.

  • UCB SA (EBR:UCB): What’s The Analyst Consensus Outlook?
    Simply Wall St.

    UCB SA (EBR:UCB): What’s The Analyst Consensus Outlook?

    In December 2018, UCB SA (EBR:UCB) announced its most recent earnings update, which revealed that the company benefited from a small tailwind, leading to a single-digit earnings growth of 5.3%.Read More...

  • PR Newswire

    Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

    - 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab - These positive results mark the longest-term data to date demonstrating ...

  • PR Newswire

    New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

    - Late breaking presentation of the Phase 2b long-term findings on the investigational molecule, bimekizumab, demonstrates complete or almost complete skin clearance in moderate-to-severe plaque psoriasis ...

  • Should UCB SA (EBR:UCB) Be Part Of Your Dividend Portfolio?
    Simply Wall St.

    Should UCB SA (EBR:UCB) Be Part Of Your Dividend Portfolio?

    A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, UCB SA (EBR:UCB) has paid a Read More...

  • PR Newswire

    Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)

    THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. "We are pleased with the Committee's recommendation to approve EVENITY for the treatment of postmenopausal women with osteoporosis at high risk for fracture," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • PR Newswire

    EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

    THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are co-developing EVENITY worldwide, with development in Japan being led by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., headquartered in Tokyo.

  • Simply Wall St.

    An Examination Of UCB SA (EBR:UCB)

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...